News Focus
News Focus
icon url

DewDiligence

03/21/24 12:34 PM

#251143 RE: DewDiligence #249417

TRML—(-36%)—suffers collateral damage_from Roche’s Enspryng trial:

https://www.fiercepharma.com/pharma/despite-positive-trial-roche-says-enspryng-fell-short-expectations-myasthenia-gravis

TRML’s TOUR006 has the same anti-IL-6 MoA as Enspryng.

TRML is the result of a 2023 reverse-merger (#msg-173043164).